A phase II trial of ImmunotheRapy with single fRactIon non-ablative raDIAtion in previously untreated patients with stage IV NSCLC. (IRRIDIATE-Lung trial)

Go Back to All Clinical Trials

A phase II trial of ImmunotheRapy with single fRactIon non-ablative raDIAtion in previously untreated patients with stage IV NSCLC. (IRRIDIATE-Lung trial)

Brief description of study

This is a phase II open label trial of pembrolizumab sequentially following upfront non-ablative focal therapy to up to five distinct metastatic subsites in de novo stage IV Non-Small Cell Lung Cancer (NSCLC). The primary goal of this trial is to evaluate the efficacy of upfront non-ablative focal radiation (RT) to index lesions as a way of enhancing the anti-tumor immune response to pembrolizumab.

Clinical Study Identifier: s22-00673

ClinicalTrials.gov Identifier: NCT05691829

Principal Investigator: Vamsidhar Velcheti.

Other Investigators: Gerard Donnelly, Elaine Shum, David Mendoza, Anna Kurzyna-Solinas, Joshua S. Silverman, Francis Arena, Elka R Travis, Joshua K Sabari, Kirby Rodriguez, Salman Rafi Punekar, Danny Perlaza, Todd J Carpenter, Marissa Rybstein, Natalia Cherkassky, Benjamin Cooper, Jagdeep Raince, Alma Nesimi, Jessica Wang, Sally Lau, Jeffrey G Schneider, Samantha VanMaanen, Thomas B. Daniels, Judith D Goldberg, James Newman, Melissa L Martinez, Jonathan W Lischalk, Moses M Tam, David Jaihun Byun.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies